Lucerum Blog
Home > Blog
Looking for something specific?
The sisters and the mystery of the resilient brain
When researchers studied the brains of Catholic sisters who had donated them after death, they found something puzzling: some women who had stayed sharp into old age had brains full of the plaques and tangles associated with Alzheimer’s disease. This post follows the Nun Study, which began in 1991 with 678 School Sisters of Notre Dame, to explore why. It covers the ideas of brain reserve and cognitive reserve, the surprising link between the “idea density” of autobiographies the sisters wrote in their early twenties and their thinking six decades later, and the way small strokes can tip Alzheimer-type changes into dementia. It also looks at what other research adds, including preserved synapses in resilient brains and evidence that older brains can still change, while being honest about what autopsies can and can’t tell us. The result is a clear look at one of the most intriguing questions in aging research: how some people keep their memories even when disease is already present.
Investigating Brain Resilience with EEG and Connectivity: Applications in Recovery and Neuromodulation
How does the brain sustain everyday abilities through aging, illness, or injury—and how could understanding its connections improve care? This article explores brain reserve and resilience through EEG and network analysis, explaining how efficiency, specialization, and robustness relate to the brain’s capacity to adapt. It examines emerging applications in cognitive aging, stroke recovery, and personalized brain stimulation, using LucerumCarto as an example of linking patient-reported difficulties with brain-network findings, treatment planning, and follow-up. The central question is practical: how can these measurements help people preserve or regain the abilities that matter to them?
Meditation, Measured: How Brain Connectivity Is Reframing an Ancient Practice
Meditation research is increasingly focused on how large-scale brain networks support trainable attention, awareness, and emotion regulation, with the default-mode, frontoparietal-control, and salience networks emerging as central systems of interest. Resting-state mapping with fMRI and source-localized qEEG can track how these networks change with practice, opening a practical path to test whether individual network changes relate to meaningful cognitive and clinical outcomes.
Sleep, Vigilance, and Seizures
Sleep is a pharmacologically active brain state. The sleep-wake cycle continuously regulates cortical excitability, with NREM transitions elevating and REM suppressing seizure susceptibility. A 2025 meta-analysis now provides robust population-level evidence that sleep deprivation measurably reduces cortical inhibition. Many drugs in routine use — across addiction medicine, psychiatry, and pain management — alter the sleep architecture that maintains this inhibitory tone. For alcohol and GABAergic sedatives, the link from sleep disruption to withdrawal seizure is mechanistically direct. For antidepressants, stimulants, and opioids, the sleep-architecture pathway adds a layer of risk that warrants consideration alongside the drugs’ direct pharmacological effects.
Measuring the Rewiring: Connectivity Biomarkers for the Next Generation of Psychiatric Drugs
For pharma teams developing neuroplastogens, from psychedelics to next-generation antidepressants, this piece lays out brain functional connectivity, obtained from EEG or fMRI, as the key biomarker for showing that a drug is reorganizing brain circuits. It covers how Lucerum's standardized qEEG methods turn connectivity into a practical, dose-tracked measure usable across every clinical trial phase, with examples from a real MDD program showing the approach in action, from healthy volunteers through patient outcomes.
Quantitative EEG in Depression: Predictors of Treatment Response
Quantitative EEG in Depression: Predictors of Treatment Response
Antidepressants and rTMS help roughly half of the patients who try them. Nobody knows which half in advance. That's a solvable problem — and quantitative EEG has quietly spent forty years solving it.
In this piece I give a broad overview of where the field actually is: the early generation of qEEG response predictors that have survived four decades of scrutiny and meta-analysis, the shift now underway toward network- and connectome-based markers that match the modern view of depression as a circuit-level disorder, and the emerging frontier of source-localized, neurotransmitter-informed EEG that could turn precision psychopharmacology from an aspiration into a workflow. I close on where things stand with the FDA and payers, and why the momentum is finally moving in the right direction.
qEEG is not a miracle. But the comparison is not qEEG-versus-perfection — it's versus-the-coin-flip. #qEEG, #Neuroscience, #BrainMapping, #Depression, #Psychiatry, #rTMS, #Antidepressants, #Psychopharmacology, #Connectomics